

Ruben Burgos-Vargas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7688089/publications.pdf>

Version: 2024-02-01

158
papers

15,088
citations

36303

51
h-index

17592

121
g-index

168
all docs

168
docs citations

168
times ranked

11799
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. <i>Rheumatology</i> , 2022, 61, 1867-1876.	1.9	11
2	A Wearable System Based on Multiple Magnetic and Inertial Measurement Units for Spine Mobility Assessment: A Reliability Study for the Evaluation of Ankylosing Spondylitis. <i>Sensors</i> , 2022, 22, 1332.	3.8	2
3	Efficacy and Safety of Tocilizumab for Polyarticular Course Juvenile Idiopathic Arthritis in the Open Label Two Year Extension of a Phase III Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 530-541.	5.6	16
4	Recommendations of the Mexican College of Rheumatology for the management of spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 37-45.	0.3	0
5	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001450.	3.8	64
6	P187 Secukinumab significantly decreased joint synovitis measured by Power Doppler ultrasonography in biologic-naïve patients with active psoriatic arthritis: primary (12week) results from a randomised, placebo-controlled Phase 3 study. <i>Rheumatology</i> , 2021, 60, .	1.9	3
7	Outcomes in Juvenile-Onset Spondyloarthritis. <i>Frontiers in Medicine</i> , 2021, 8, 680916.	2.6	5
8	Results from a cross-sectional, observational study to assess inadequate pain relief in patients with knee and/or hip osteoarthritis in Mexico. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 397-403.	0.3	3
9	Results from a cross-sectional, observational study to assess inadequate pain relief in patients with knee and/or hip osteoarthritis in Mexico. <i>Reumatología Clínica</i> , 2021, 17, 397-403.	0.5	3
10	Inflammatory Foot Involvement in Spondyloarthritis: From Tarsitis to Ankylosing Tarsitis. <i>Frontiers in Medicine</i> , 2021, 8, 730273.	2.6	3
11	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001728.	3.8	5
12	Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement. <i>Clinical Rheumatology</i> , 2021, , 1.	2.2	5
13	Preliminary tests of an Inertial Measurement Units based System for Spine mobility assessment in patients with Ankylosing Spondylitis. , 2021, 2021, 7124-7127.		1
14	Consenso ASAS en nomenclatura en español para las espondiloartritis. <i>Reumatología Clínica</i> , 2020, 16, 333-338.	0.5	4
15	Are Target Urate and Remission Possible in Severe Gout? A Five-year Cohort Study. <i>Journal of Rheumatology</i> , 2020, 47, 132-139.	2.0	14
16	Differential expression of TLR2 and TLR4 in $\hat{I}^{\pm 4}27$ -positive leukocytes of patients with axial spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 879-888.	1.9	3
17	Peripheral neuropathies in rheumatic diseases: More diverse and frequent than expected. A cross-sectional study. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 226-232.	1.9	1
18	Determinants of discordance between criteria for inactive disease and low disease activity in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2020, 73, 1722-1729.	3.4	3

#	ARTICLE	IF	CITATIONS
19	Association of ERAP2 polymorphisms in Colombian HLA-B27+ or HLA-B15+ patients with SpA and its relationship with clinical presentation: axial or peripheral predominance. <i>RMD Open</i> , 2020, 6, e001250.	3.8	5
20	Syndemic and syndemogenesis of low back pain in Latin-American population: a network and cluster analysis. <i>Clinical Rheumatology</i> , 2020, 39, 2715-2726.	2.2	13
21	Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). <i>Rheumatology</i> , 2020, 59, 2774-2784.	1.9	31
22	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	3.4	73
23	Stress proteins in the pathogenesis of spondyloarthritis. <i>Rheumatology International</i> , 2019, 39, 595-604.	3.0	2
24	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1550-1558.	0.9	171
25	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 255-263.	5.6	120
26	Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 43-53.	0.3	0
27	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. <i>Journal of Rheumatology</i> , 2019, 46, 190-197.	2.0	318
28	Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies. <i>Reumatología Clínica</i> , 2019, 15, 43-53.	0.5	1
29	Subclinical synovitis and tenosynovitis by ultrasonography (US) 7 score in patients with rheumatoid arthritis treated with synthetic drugs, in clinical remission by DAS28. <i>Reumatología Clínica</i> , 2019, 15, e5-e9.	0.5	3
30	Extension Study of PF-05280586 , a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 1598-1606.	3.4	22
31	Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 1885-1894.	2.2	6
32	The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 283-289.	3.0	0
33	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2018-213030.	0.9	183
34	The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 307-313.	3.0	0
35	Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 206-212.	2.0	31
36	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1311-1317.	0.9	85

#	ARTICLE	IF	CITATIONS
37	Severe tophaceous gout and disability: changes in the past 15 years. <i>Clinical Rheumatology</i> , 2017, 36, 199-204.	2.2	9
38	Function of Treg Cells Decreased in Patients With Systemic Lupus Erythematosus Due To the Effect of Prolactin. <i>Medicine (United States)</i> , 2016, 95, e2384.	1.0	27
39	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	3.4	48
40	Reply. <i>Arthritis Care and Research</i> , 2016, 68, 1053-1054.	3.4	1
41	Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia. <i>Rheumatology International</i> , 2016, 36, 643-651.	3.0	12
42	Epidemiology of rheumatic diseases in indigenous populations in Latin-Americans. <i>Clinical Rheumatology</i> , 2016, 35, 1-3.	2.2	12
43	Computer vision system for evaluating the Schober's test. <i>AIP Conference Proceedings</i> , 2016, , .	0.4	0
44	Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. <i>Medicine (United States)</i> , 2016, 95, e5652.	1.0	72
45	The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study. <i>Arthritis Research and Therapy</i> , 2016, 18, 132.	3.5	42
46	Reactive Arthritis. , 2016, , 563-570.e3.		0
47	The Social Gap Index and the prevalence of osteoarthritis in the community: a cross-sectional multilevel study in Mexico. <i>Clinical Rheumatology</i> , 2016, 35, 175-182.	2.2	13
48	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1958-1963.	0.9	383
49	Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Entesitis-related Arthritis, or Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 816-824.	2.0	46
50	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1016-1023.	0.9	188
51	If three of my brothers have ankylosing spondylitis, why does the doctor say it is not necessarily hereditary? The meaning of risk in multiplex case families with ankylosing spondylitis. <i>Chronic Illness</i> , 2016, 12, 58-70.	1.5	1
52	Bone Proliferation in Ankylosing Tarsitis Might Involve Mechanical Stress, and Hormonal and Growth Factors. <i>Journal of Rheumatology</i> , 2015, 42, 2210-2210.	2.0	5
53	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , 2015, 6, 7146.	12.8	220
54	A Prospective Follow-Up of Adipocytokines in Cohort Patients With Gout. <i>Medicine (United States)</i> , 2015, 94, e935.	1.0	4

#	ARTICLE	IF	CITATIONS
55	Long-Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years. <i>Arthritis and Rheumatology</i> , 2015, 67, 2759-2770.	5.6	64
56	A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 1503-1512.	3.4	84
57	ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1627-1629.	0.9	86
58	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015, 67, 1237-1245.	3.4	88
59	Association of Regional and Cultural Factors With the Prevalence of Rheumatoid Arthritis in the Mexican Population. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 57-62.	0.9	18
60	Coping Strategies for Health and Daily-Life Stressors in Patients With Rheumatoid Arthritis, Ankylosing Spondylitis, and Gout. <i>Medicine (United States)</i> , 2015, 94, e600.	1.0	23
61	Bone Lineage Proteins in the Enteses of the Midfoot in Patients with Spondyloarthritis. <i>Journal of Rheumatology</i> , 2015, 42, 630-637.	2.0	17
62	Juvenile-onset spondyloarthritis. , 2015, , 862-867.		0
63	A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment. <i>Arthritis and Rheumatology</i> , 2014, 66, S218-S219.	5.6	0
64	Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1114-1122.	0.9	106
65	A3: Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, S4.	5.6	6
66	A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, S23-S24.	5.6	5
67	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014, 66, S17-S18.	5.6	4
68	Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 379-389.	5.6	289
69	Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration. <i>Pediatric Rheumatology</i> , 2014, 12, 49.	2.1	6
70	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 328-335.	0.9	222
71	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. <i>Arthritis and Rheumatology</i> , 2014, 66, 2649-2656.	5.6	81
72	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.9	397

#	ARTICLE	IF	CITATIONS
73	Characterization of Knee Osteoarthritis in Latin America. A Comparative Analysis of Clinical and Health Care Utilization in Argentina, Brazil, and Mexico. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 152-159.	0.3	0
74	Characterization of Knee Osteoarthritis in Latin America. A Comparative Analysis of Clinical and Health Care Utilization in Argentina, Brazil, and Mexico. <i>Reumatología Clínica</i> , 2014, 10, 152-159.	0.5	22
75	Usage Problems and Social Barriers Faced by Persons With a Wheelchair and Other Aids. Qualitative Study From the Ergonomics Perspective in Persons Disabled by Rheumatoid Arthritis and Other Conditions. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 24-30.	0.3	5
76	Current therapies in rheumatoid arthritis: A Latin American perspective. <i>Reumatología Clínica</i> , 2013, 9, 106-112.	0.5	50
77	From undifferentiated SpA to ankylosing spondylitis. <i>Nature Reviews Rheumatology</i> , 2013, 9, 639-641.	8.0	6
78	Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results. <i>Journal of Rheumatology</i> , 2013, 40, 113-126.	2.0	87
79	Problemas con el uso de sillas de ruedas y otras ayudas técnicas y barreras sociales a las que se enfrentan las personas que las utilizan. Estudio cualitativo desde la perspectiva de la ergonomía en personas discapacitadas por enfermedades reumáticas y otras condiciones. <i>Reumatología Clínica</i> , 2013, 9, 24-30.	0.5	10
80	Current therapies in rheumatoid arthritis: A Latin American perspective. <i>Reumatología Clínica (English)</i> 2013, 9, 106-112.	0.3	2
81	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. <i>Nature Genetics</i> , 2013, 45, 730-738.	21.4	699
82	A Community-Based Study on the Prevalence of Spondyloarthritis and Inflammatory Back Pain in Mexicans. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 57-61.	0.9	16
83	'Not-Belonging': Illness Narratives of Mexican Patients with Ankylosing Spondylitis. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2013, 32, 487-500.	1.2	9
84	Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1991-1997.	0.9	103
85	Juvenile Spondyloarthritis Treatment Recommendations. <i>American Journal of the Medical Sciences</i> , 2012, 343, 367-370.	1.1	16
86	Comparison of the Clinical Expression of Patients with Ankylosing Spondylitis from Europe and Latin America. <i>Journal of Rheumatology</i> , 2012, 39, 2315-2320.	2.0	44
87	Catastrophic health expenses and impoverishment of households of patients with rheumatoid arthritis. <i>Reumatología Clínica</i> , 2012, 8, 168-173.	0.5	47
88	Inflammatory Back Pain. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 487-499.	1.9	7
89	Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial. <i>Journal of Rheumatology</i> , 2012, 39, 1859-1866.	2.0	44
90	In Vivo Peripheral Blood Proinflammatory T Cells in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2012, 39, 830-835.	2.0	53

#	ARTICLE	IF	CITATIONS
91	The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist. <i>Pediatric Rheumatology</i> , 2012, 10, 14.	2.1	59
92	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 2385-2395.	27.0	716
93	Catastrophic health expenses and impoverishment of households of patients with rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2012, 8, 168-173.	0.3	27
94	The diagnostic value of the proposal for clinical gout diagnosis (CGD). <i>Clinical Rheumatology</i> , 2012, 31, 429-434.	2.2	22
95	Juvenile Ankylosing Spondylitis. , 2012, , 1601-1609.		2
96	Epidemiology of Rheumatic Diseases. A Community-Based Study in Urban and Rural Populations in the State of Nuevo Leon, Mexico. <i>Journal of rheumatology Supplement, The</i> , 2011, 86, 9-14.	2.2	34
97	Epidemiology of the Rheumatic Diseases in Mexico. A Study of 5 Regions Based on the COPCORD Methodology. <i>Journal of rheumatology Supplement, The</i> , 2011, 86, 3-8.	2.2	200
98	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 905-908.	0.9	365
99	REACTIVE ARTHRITIS. , 2011, , 591-599.		1
100	Epidemiology of Spondyloarthritis in México. <i>American Journal of the Medical Sciences</i> , 2011, 341, 298-300.	1.1	15
101	Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. <i>Clinical Rheumatology</i> , 2011, 30, 1589-1593.	2.2	35
102	Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 1262-1270.	3.4	27
103	Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural. <i>Arthritis and Rheumatism</i> , 2011, 63, 609-621.	6.7	369
104	Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial. <i>Arthritis and Rheumatism</i> , 2011, 63, 1543-1551.	6.7	125
105	Towards Elucidation of the Epidemiology of the Rheumatic Diseases in Mexico. COPCORD Studies in the Community. <i>Journal of rheumatology Supplement, The</i> , 2011, 86, 1-2.	2.2	13
106	Prevalence of Rheumatic Regional Pain Syndromes in Adults from Mexico: A Community Survey Using COPCORD for Screening and Syndrome-specific Diagnostic Criteria. <i>Journal of rheumatology Supplement, The</i> , 2011, 86, 15-20.	2.2	29
107	Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease. <i>Journal of Rheumatology</i> , 2011, 38, 1656-1660.	2.0	77
108	Prevalence of Back Pain in the Community. A COPCORD-Based Study in the Mexican Population. <i>Journal of rheumatology Supplement, The</i> , 2011, 86, 26-30.	2.2	18

#	ARTICLE	IF	CITATIONS
109	ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 249-251.	0.9	208
110	Validity of the COPCORD Core Questionnaire as a Classification Tool for Rheumatic Diseases. <i>Journal of rheumatology Supplement, The</i> , 2011, 86, 31-35.	2.2	34
111	The juvenile-onset spondyloarthropathies. , 2011, , 1029-1034.e1.		0
112	Challenges in juvenile-onset spondyloarthritis. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 229-239.	0.3	2
113	Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. <i>Arthritis Care and Research</i> , 2010, 62, 63-72.	3.4	207
114	Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1792-1802.	6.7	204
115	From Retrospective Analysis of Patients with Undifferentiated Spondyloarthritis (SpA) to Analysis of Prospective Cohorts and Detection of Axial and Peripheral SpA. <i>Journal of Rheumatology</i> , 2010, 37, 1091-1095.	2.0	12
116	Diagnosis of Chronic Gout: Evaluating the American College of Rheumatology Proposal, European League Against Rheumatism Recommendations, and Clinical Judgment. <i>Journal of Rheumatology</i> , 2010, 37, 1743-1748.	2.0	55
117	The 30-kDa band from <i>Salmonella typhimurium</i> : IgM, IgA and IgG antibody response in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2009, 48, 748-754.	1.9	9
118	A case of childhood-onset ankylosing spondylitis: diagnosis and treatment. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 52-57.	3.2	8
119	Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 335-344.	6.7	216
120	The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. <i>Arthritis and Rheumatism</i> , 2009, 60, 1895-1905.	6.7	501
121	Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2009, 28, 1135-1139.	2.2	13
122	Validation of the Health Assessment Questionnaire disability index in patients with gout. <i>Arthritis and Rheumatism</i> , 2008, 59, 665-669.	6.7	63
123	Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008, 58, 3309-3318.	6.7	313
124	Ankylosing spondylitis and reactive arthritis in the developing world. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 709-723.	3.3	14
125	Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. <i>Lancet, The</i> , 2008, 372, 383-391.	13.7	486
126	Vitiligo Improvement in a Patient with Ankylosing Spondylitis Treated with Infliximab. <i>Dermatology</i> , 2008, 216, 234-235.	2.1	36

#	ARTICLE	IF	CITATIONS
127	The Use of Glucocorticoids by Rheumatologic Patients Before Attending a Specialized Department in MÃ©xico. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 148-152.	0.9	5
128	Chapter 2 The Juvenile-Onset Spondyloarthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2007, , 15-33.	0.1	1
129	Undifferentiated spondyloarthritis: A global perspective. <i>Current Rheumatology Reports</i> , 2007, 9, 361-366.	4.7	12
130	Tumor Necrosis Factor-Î± Promoter Polymorphisms in Mexican Patients With Spondyloarthritis. <i>Human Immunology</i> , 2006, 67, 826-832.	2.4	36
131	The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement. <i>Arthritis and Rheumatism</i> , 2006, 55, 355-363.	6.7	72
132	A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2989-2996.	6.7	133
133	Response to Expression of Concern Regarding VIGOR Study. <i>New England Journal of Medicine</i> , 2006, 354, 1196-1199.	27.0	35
134	Anti-tumor necrosis factor Î± blockade in the treatment of juvenile spondylarthropathy. <i>Arthritis and Rheumatism</i> , 2005, 52, 2103-2108.	6.7	104
135	CD4 and CD8 T cell response to the rHSP60 from <i>Klebsiella pneumoniae</i> in peripheral blood mononuclear cells from patients with ankylosing spondylitis. <i>Revista De Investigacion Clinica</i> , 2005, 57, 555-62.	0.4	8
136	Primary prevention in rheumatology: the importance of hyperuricemia. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 111-124.	3.3	39
137	A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 2191-2201.	6.7	307
138	Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. <i>Human Immunology</i> , 2004, 65, 1437-1442.	2.4	29
139	Metabolic Syndrome and Ischemic Heart Disease in Gout. <i>Journal of Clinical Rheumatology</i> , 2004, 10, 105-109.	0.9	54
140	Pharmacokinetics of Meloxicam in Patients With Juvenile Rheumatoid Arthritis. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 866-872.	2.0	22
141	Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. <i>Gastroenterology</i> , 2003, 124, 288-292.	1.3	336
142	Innate immunity in host-microbial interactions: Beyond B27 in the spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 2002, 14, 373-382.	4.3	20
143	The juvenile-onset spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2002, 28, 531-560.	1.9	52
144	The juvenile-onset spondyloarthritis: rationale for clinical evaluation. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 551-572.	3.3	21

#	ARTICLE	IF	CITATIONS
145	Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. <i>Arthritis and Rheumatism</i> , 2002, 47, 242-248.	6.7	82
146	High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002, 29, 1079-83.	2.0	14
147	The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. <i>International League of Associations for Rheumatology. Journal of Rheumatology</i> , 2002, 29, 869-74.	2.0	34
148	Recognition of B cells epitopes of the <i>Klebsiella pneumoniae</i> GroEL-like protein by HLA-B27 positive subjects. <i>Microbial Pathogenesis</i> , 2000, 28, 211-220.	2.9	9
149	Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1520-1528.	27.0	3,651
150	Comparison of two schedules for administering oral low-dose methotrexate (weekly versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 T randomized study. <i>Arthritis and Rheumatism</i> , 1999, 42, 2160-2165.	6.7	20
151	FEATURES OF SPONDYLOARTHRITIS AROUND THE WORLD. <i>Rheumatic Disease Clinics of North America</i> , 1998, 24, 753-770.	1.9	73
152	The LMP2 polymorphism is associated with susceptibility to acute anterior uveitis in HLA-B27 positive juvenile and adult Mexican subjects with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 488-492.	0.9	37
153	JUVENILE-ONSET SPONDYLOARTHROPATHIES. <i>Rheumatic Disease Clinics of North America</i> , 1997, 23, 569-598.	1.9	78
154	The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 835-844.	6.7	116
155	Characterization of B27 haplotypes by oligotyping and genomic sequencing in the Mexican Mestizo population with ankylosing spondylitis: Juvenile and adult onset. <i>Human Immunology</i> , 1995, 43, 174-180.	2.4	36
156	Spondyloarthropathies and psoriatic arthritis in children. <i>Current Opinion in Rheumatology</i> , 1993, 5, 634-643.	4.3	29
157	JUVENILE ANKYLOSING SPONDYLITIS. <i>Rheumatic Disease Clinics of North America</i> , 1992, 18, 123-142.	1.9	23
158	Clinical Experiences with the Intramuscular Injection of Tiaprofenic Acid in Rheumatic Diseases, with Particular Emphasis on Time of Onset and Duration of the Analgesic Effect1. <i>Drugs</i> , 1988, 35, 72-80.	10.9	6